Combined antitumor efficacy of a new tanshinone IIA analog and irinotecan with alleviating gastrointestinal side effect

Key Points

• Combination therapy improves antitumor efficacy while alleviating gastrointestinal side effects.
• The new tanshinone IIA analog enhances the effectiveness of irinotecan in tumor treatment.
• Assessment of gastrointestinal side effects finds significant reduction with the combination therapy compared to irinotecan alone.
• Supports further exploration of tanshinone IIA analogs in clinical settings for cancer therapy.